<DOC>
	<DOCNO>NCT02603419</DOCNO>
	<brief_summary>This Phase 1b dose-finding study evaluate pharmacokinetics , pharmacodynamics , preliminary antitumor activity avelumab ( MSB00100718C ) adult patient relapse refractory classical Hodgkin 's Lymphoma ( cHL ) . Patients enrol study require fail prior course high dose chemotherapy part first-line salvage chemotherapy regimen cHL . The primary purpose study ass pharmacokinetics , biological activity early sign efficacy various avelumab dose regimen patient cHL .</brief_summary>
	<brief_title>Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin 's Lymphoma ( JAVELIN HODGKINS )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Histological confirmation classical Hodgkin 's Lymphoma ( cHL ) relapse refractory disease At least 1 FDGPETavid ( Deauville 4/5 ) measurable lesion &gt; 1.5 cm define Response Criteria Malignant Lymphoma A pretreatment tumor biopsy ( lymph node bone marrow ) mandatory baseline expansion phase . A pretreatment tumor biopsy lead phase ontreatment biopsy phase optional . Prior allogeneic stem cell transplantation patient dose expansion cohort Prior therapy antiPD1 antiPDL1 . May enrol patient stop prior antiPD1 therapy one year ago respond . Systemic anticancer therapy le 2 week study entry Prior palliative radiotherapy lesion ( ) permit long least one target lesion evaluable antitumor activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>classical Hodgkins Lymphoma ( relapsed/refractory )</keyword>
	<keyword>anti PD-L1</keyword>
	<keyword>Phase 1</keyword>
	<keyword>PK</keyword>
	<keyword>Receptor occupancy</keyword>
	<keyword>Immunophenotypic biomarkers</keyword>
</DOC>